Cell Therapy News

Kite Pharma submitted a supplemental biologics license application to the FDA for brexucabtagene autoleucel to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, according to the agent’s manufacturer.

Steroids are commonly used to mitigate severe treatment-related adverse events associated with chimeric antigen receptor T-cell therapy.

The FDA cleared an investigational new drug application for the combination of AFM24 and SNK-01 in patients with solid tumors that express epidermal growth factor receptor, according to a joint press release from each agent’s manufacturer.

The FDA approved idecabtagene vicleucel, a chimeric antigen receptor T-cell therapy, for treatment of adults with relapsed or refractory multiple myeloma.

Although chimeric antigen receptor T-cell therapies are being administered more frequently, they are still available only at a limited number of specialized centers.

In this video, Kelly K. Hunt, MD, FACS, FSSO, professor and chair of the department of breast surgical oncology at The University of Texas MD Anderson Cancer Center, discussed upcoming debates on targeted therapies at the 38th Annual Miami Breast Cancer Conference. Hunt said she was excited to participate in debates on best timing and options in emerging therapies for patients.

In this video, Kelly K. Hunt, MD, FACS, FSSO, professor and chair of the department of breast surgical oncology at The University of Texas MD Anderson Cancer Center, highlighted updated presentations in immunotherapy at the virtual 38th Annual Miami Breast Cancer Conference.

Chimeric antigen receptor T-cell therapy employs a patient’s immune system to fight cancer and thereby weakens it, leaving the recipient vulnerable to infection.

The FDA has granted orphan drug designation for chemically induced photoreceptor-like cells to treat retinitis pigmentosa, according to a press release from CiRC Biosciences.

The Parker Institute for Cancer Immunotherapy awarded nearly $3 million worth of grants to six early career researchers.